Clinical Trial Update: AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating AMG 102 in combination with erlotinib in advanced non-small cell lung cancer has completed and results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AMG 102 (AMG 102)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Ahmad Tarhini | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-09-01